An open trial of internet-based treatment of depression symptoms in older adults

Not Applicable

Completed

• Conditions: Depression; Mental Health - Depression

• Registration Number: ACTRN12611000009910
• Lead Sponsor: Clinical Research Unit for Anxiety and Depression (CRUfAD), St Vincent's Hospital (Sydney)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-01-06
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Resident of Australia
- Have access to a computer, the Internet, and use of a printer
- Not currently participating in CBT
- Not using illicit drugs or consuming more than three standard drinks/day
- Not currently experiencing a psychotic mental illness or severe symptoms of depression (defined as a total score >19 or responding >2 to Question 9 [suicidal ideation] on the PHQ-9)
- Reports that they have been assessed by a GP or specialist to rule out a physical cause for their depression
- A total score >9 on the PHQ-9 (indicating at least elevated symptoms of depression). Note that meeting diagnostic criteria for depression is NOT an inclusion criteria – instead, participants need to have elevated symptoms of depression as measured by the PHQ-9
- If taking medication for anxiety or depression, been taking the same dose for at least 1 month and not intend to change that dose during the course of the program
- Prepared to provide name, phone number and address, and to provide the name and address of a local general practitioner
- Prepared to provide informed consent

Exclusion Criteria

- Severe depression (score of 20 or greater on PHQ-9)
- Suicidal intent or plan
- Scoring below cut-off on the PHQ-9
- Current substance abuse
- Psychosis
- Presenting problem not depression

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Symptoms and severity of depression is measured by the Patient Health Questionnaire-9 (PHQ-9)[Administered at pre-treatment, prior to each Lesson in the program, post-treatment, and at 3-months post-treatment];Anxiety is measured by the Generalised Anxiety Disorder 7 Item Scale (GAD-7).[Administered at pre-treatment, prior to each Lesson in the program, post-treatment, and at 3-months post-treatment];Symptoms and severity of depression is measured by the Geriatric Depression Scale (GDS)[Administered at pre-treatment, post-treatment, and at 3-months post-treatment.]

Secondary Outcome Measures

Name	Time	Method
Depression, Anxiety and Stress is measured by the Depression, Anxiety, Stress Scale (21 item) (DASS-21).[Administered at pre-treatment, post-treatment, and at 3-months post-treatment.];Disability will be measured by the World Health Organisation Disability Assessment Schedule 2nd Edition (WHODAS-II).[Administered at pre-treatment, post-treatment, and at 3-months post-treatment.];Psychological distress is measured by the Kessler 10-item scale (K-10).[Administered at pre-treatment, post-treatment, and at 3-months post-treatment.];Neuroticism is measured by using the NEO-Five Factor Inventory (NEO-FFI) Neuroticism scale.[Administered at pre-treatment, post-treatment, and at 3-months post-treatment.];Perception of cognitive health is measured by the Cognitive Failures Questionnaire (CFQ).[Administered at pre-treatment, post-treatment, and at 3-months post-treatment.]